| Authors: |
Horton JR; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Pathuri S; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wong K; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., Ren R; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Rueda L; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., Fosbenner DT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., Heerding DA; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., McCabe MT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., Pappalardi MB; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA., Zhang X; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., King BW; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA. Electronic address: bryan.w.king@gsk.com., Cheng X; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: xcheng5@mdanderson.org. |
